Diagnosis and Management of VTE



Similar documents
New Oral Anticoagulants

Pulmonary Embolism Treatment Update

Diagnosis and Treatment of VTE in the ER

Venous Thromboembolic Treatment Guidelines

ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014

Guidelines for diagnosis and management of acute pulmonary embolism

Acute behandeling van longembolie. Peter Verhamme. Bloedings- en Vaatziekten UZ Leuven. Research support and/or honoraria:

National Guidance and New Protocols

Paul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, A. Objective

National Guidance and New Protocols

Conserva)ve Treatment of PE/ DVT

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

DVT/PE Management with Rivaroxaban (Xarelto)

Information for you Treatment of venous thrombosis in pregnancy and after birth. What are the symptoms of a DVT during pregnancy?

Thrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003

To define a diagnostic algorithm and treatment strategy for patients with acute pulmonary embolism.

New Oral Anticoagulants. How safe are they outside the trials?

1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using

Innovations in Treating VTE, Using the EDOU

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013

NQF #IEP Pulmonary CT Imaging for Patients at Low Risk for Pulmonary Embolism

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285:

High Risk Emergency Medicine

Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

Rivaroxaban to prevent blood clots for patients who have a lower limb plaster cast. Information for patients Pharmacy

ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν

Raising the Bar: Risk Stratifying VTE & Literature Update

Thrombosis and Hemostasis

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

New Anticoagulants: What to Use What to Avoid

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

Update on the Diagnosis and Treatment of Venous Thromboembolism Daniel B. DiCola, MD and Paul Ament, Pharm.D Excela Heath, Latrobe, PA

Anticoagulation For Atrial Fibrillation

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Direct Oral Anticoagulants (DOACs) Who Gets What?

New Anticoagulants: When and Why Should I Use Them? Disclosures

Antithrombotic Therapy for VTE Disease

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery

Antithrombotic Therapy for VTE Disease

Novel Therapy for Acute Pulmonary Embolism Joe Adams, MD Cardiology Associates of North Mississippi

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther

New Anticoagulants and GI bleeding

Gruppo di lavoro: Malattie Tromboemboliche

Confirmed Deep Vein Thrombosis (DVT)

Hypercoagulable States

3/3/2015. Patrick Cobb, MD, FACP March 2015

Preventing Blood Clots in Adult Patients. Information For Patients

New in Atrial Fibrillation

The Prescribing pathway consists of a number of parts:

A PATIENT S GUIDE TO PULMONARY EMBOLISM TREATMENT

Long-Term Anticoagulant Therapy: Clinical Decision and Therapeutic Strategies. Kenneth A. Bauer, MD Harvard Medical School Boston, MA USA

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

10/10/13. Anil Chopra University Health Network University of Toronto

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

Case III. Disscussion. the UHP ultrasound protocol. Novel Ultrasound Approach to the Empiric Evaluation of the Undifferentiated Hypotensive Patient

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

The Role of the Newer Anticoagulants

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Joseph A. Caprini, MD, MS, FACS, RVT

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

Making the Case for CPG s Jean Luciano, MSN, RN, CNRN, SCRN, CRNP, FAHA Claranne Mathiesen, MSN, RN, CNRN, SCRN, FAHA

Inconsistencies in the Use of Cardiac Biomarkers or Echocardiography in Patients with Acute Non-Massive Pulmonary Embolism

FULL REVIEW. PBS listing. Rivaroxaban (Xarelto) NPS RADAR AUGUST 2013 KEY POINTS

Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF

Limitations of VKA Therapy

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

DOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant

Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師

Epidemiology of Pulmonary Embolism. 1,500,000 new cases per year

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital

Service Specification Template Department of Health, updated June 2015

Transcription:

Diagnosis and Management of VTE Tracy Minichiello, M.D. Professor of Medicine University of California, San Francisco Chief, SF VA Anticoagulation & Thrombosis Service Disclosures I have nothing to disclose 1

TOPICS Diagnostic algorithm for DVT/PE Risk stratification for PE Thrombolysis for submassive PE Thrombophilia work up Duration of anticoagulation for VTE CASE #1 A 55 yo morbidly obese man presents with pain and swelling in his calf. Right calf is 4 cm greater than left. A proximal leg ultrasound is negative for DVT. You: 1) Send him home. DVT ruled out. 2) Get a d-dimer 1 st and if negative send him home. DVT ruled out. 3) Send him home without d-dimer but have him return for repeat ultrasound in 1 week 2

it Or if u/s non diagnostic For patients with moderate pre test probability: If u/s of proximal veins only will need repeat u/s in one week UNLESS d-dimer negative For high pretest Prob start with u/s. cannot use d-dimer alone Repeat u/s in 1 week ACCP Guideline Imaging Whole leg ultrasound preferred if low probability of returning for serial studies or severe symptoms c/w calf vein thrombosis Follow up imaging Isolated calf vein thrombosis and no tx Mod/high pretest prob, + d-dimer, prox u/s: get repeat u/s in 1 week Extensive swelling and positive d-dimer or no d-dimer and u/s negative-look for iliac vein thrombus 3

Recurrent DVT diagnosis Use highly sensitive d-dimer over moderately sensitive d-dimer If initial u/s is negative and d-dimer is negative DVT ruled out. If initial u/s is negative and d-dimer is positive or not done then get repeat u/s on day 7 If initial u/s is abnormal but not clearly positive get repeat u/s on day 2 and day 7 CASE #1 A 55 yo morbidly obese man presents with pain and swelling in his calf. Right calf is 4 cm greater than left. A proximal leg ultrasound is negative for DVT. You: 1) Send him home. DVT ruled out. 2) Get a d-dimer 1 st and if negative send him home. DVT ruled out. 3) Send him home without d-dimer but have him return for repeat ultrasound in 1 week 4

CASE #2 A 65 year-old man presents with pleuritic chest pain. His BP is 120/70, HR 95, RR is 18, and his O2 sat is 98%. His physical exam is unremarkable. You determine he is low probability for PE. Case #2 You would consider PE ruled out in this gentleman if d-dimer is less than: 1) 500 mcg/l 2) 650 mcg/l 3) Hold please. I need to look this one up. 5

Determining Pretest Probability of PE WELLS: modified-includes clinician judgment ;has been evaluated in small studies on inpatients 80-99% NPV if score 4 Geneva: simplified revisedoutpatients only Miniati/Charlotte Clinician s gestalt Posadas-Martinex. Thromb Reseach 2014.Bahi J Hosp Med 2011: Ceriani et al J Thromb Haemost. 2010 Penazola et al Ann Emerg Med 2013 6

Age Adjusted D-dimer in Low/Int Prob PE Age (yrs)x 10 mcg/l Figure Legend: Righini et al ADJUST-PE study JAMA. 2014 6 highly sensitive d-dimer assays used Date of download: 10/9/2014 Copyright 2014 American Medical Association. All rights reserved. Age Adjusted D- Dimer to Rule Out PE 3 month failure rate of d-dimer between 500 and age adjusted cut off was 0.3% pts> 75 yo - % of pts in whom PE could be excluded from 6% to 30% 1 in 3.4 would have PE ruled out with age adjusted vs 1 in 16 if not adjusted Righini et al ADJUST PE study JAMA. 2014 Date of download: 10/9/2014 7

Case #2 You would consider PE ruled out in this gentleman if highly sensitive d-dimer is less than: 1) 500 mcg/l 2) 650 mcg/l 3) I can never remember the cut off. CASE #2a His d-dimer returns. It is 2000 mcg/l. A CTa shows multiple pulmonary emboli. What is this patient's risk of early mortality related to PE? A) 1% B) 15% C) 30% 8

Pulmonary Embolism Severity Index Risk Factor points Age age Male 10 Cancer 30 Heart failure 10 Chronic lung 10 disease HR > 110 20 SBP < 100 mmhg 20 RR >30 20 Temp < 36 20 Δ mental status 60 O2 sat <90% 20 Aujesky et al Eur Heart Journal 2006 class Points 30 day mortality I 0-65 <1.7% II 66-85 <3.5% III 86-105 <7.1% IV 106-125 4-11% V >125 10-25% Simplified Pulmonary Embolism Severity Index Risk Factor points Age 1 if > 80 Cancer 1 Heart failure lung 1 disease SBP < 100 mmhg 1 O2 sat <90% 1 Severity class Points 30 day mortality LOW 0 1% HIGH 1 or more 10% Jimenez, D. et al. Arch Intern Med 2010 9

Hestia Criteria Hestia criteria Zondag et al Journal of Thrombosis and Haemostasis, 11 APR 2013 10

IDENTIFICATION OF HIGH RISK NORMOTENSIVE PATIENTS WITH PE Mortality 1% 15-20% Jiménez D et al. Thorax 2011;66:75-81 Pulmonary embolism protocol Ahmad N et al. Thorax 2011 11

CASE #2 What is this patient's risk of early mortality related to PE? A) 1% B) 15% C) 30% 65 yo male with PMHx, normal VS except HR 95 PESI II Simplified PESI 0 Hestia negative Case #3 You decide to a) Admit the patient for anticoagulation and monitoring b) Discharge patient to home with LMWH/warfarin or rivaroxaban and arrange close follow up as outpatient 12

Outpatient Treatment of Pulmonary Embolism (OPTE) outcome Out N=171 In N=168 Difference in %age p value Recurrent 1 0 0.6% 0.01 VTE Major 3 0 1.8% 0.08 bleed* Mortality 1 1 0.6% 0.05 Excluded: O2 sat < 90%, SBP<100, chest pain active or high risk bleeding, recent CVA GIB in past 2 weeks, plt<75k, crcl < 30, wt > 150 kg, anticoagulation failure, poor follow up If discharged called every day for one week major bleeds-2 IM hematomas day 3/13; 1 DUB day 50 No difference in #hospital readmissions, ED visits, in 90 days LOS 0.5 days vs 3.9 days Aujesky D. et al. Lancet. 2011 Jul 2;378 How Long is Long Enough? Aujesky Arch Intern Med. 2008 13

PESI 48 Case #4a A 55 year old man presents with sudden onset chest pain and shortness of breath. A CT shows saddle PE. BP is 120/85 HR 115 O2 sat 92% on RA. ECG with right heart strain. Echo confirms right heart strain with RV dilation and loss of inspiratory collapse. You a) Treat with heparin b) Treat with thrombolytics and heparin 14

Thrombolysis for Submassive PE Thrombolysis for Submassive PE 15

PEITHO Trial Major bleed 11% v 2.4% > 75 highest risk Meyer NEJM 2014 Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage: A Meta-analysis Mortality with lysis 2.17% vs 3.89% without; NNT 59 : Risk of recurrent PE 1.17% vs 3.04% Major bleed 9.24% vs 3.42% NNH 18 (not ed if 65 yo) ICH 1.46% vs 0.19% NNH 78 Chaterjee JAMA 2014 Date of download: 8/12/2014 16

MOPPET Trial Case #4a A 55 year old man presents with sudden onset chest pain and shortness of breath. A CT shows saddle PE. BP is 120/85 HR 115 O2 sat 92% on RA. ECG with right heart strain. Echo confirms right heart strain with RV dilation and loss of inspiratory collapse. You a)treat with heparin b)consider thrombolytics and heparin Get troponin,? U/S LE Consider half dose esp if <65 kg 17

Case #4b Should you send a thrombophilia work up on this gentleman? a) Yes b) No Impact of Thrombophilia on Recurrence Risk Patient group Recurrence of VTE per Year total 2.6% 1 thrombophilia defect 2.5% Iniitial VTE provoked 1.8% Initial VTE unprovoked 3.3% Unprovoked with thrombophilia 3.4% Unprovoked without thrombophilia 3.2% Christiansen JAMA 2005 Shulman Amer j Med 1998 18

Impact of Acute Thrombosis & Anticoagulation on Thrombophilia Testing test Acute VTE Heparin Warfarin Anticardiolipin antibodies Lupus anticoagulant May be elevated May be prolonged no effect prolonged no effect prolonged Protein C, S decreased No effect decreased Antithrombin level decreased decreased increased Factor VIII level increased no effect no effect TSOAC and Thrombophilia Testing Mani et al White Paper Siemans 2013 19

Work up for Laboratory Thrombophilia Women of childbearing years Patients with suspicion for APLS Strong family history of VTE Patients with recurrent VTE Thrombosis in weird places Results will influence therapy If done prefer to do when out of acute phase (after 3 months/except when high suspicion for APLS) Case #5a:How long will you recommend this patient stay on anticoagulation? 55 yo man with unprovoked PE? a) 3 months b) 6 months c) 12 months d) Indefinitely 20

Case #5b:How long will you recommend this patient stay on anticoagulation? 68 yo woman with provoked PE? a) 3 months b) 6 months c) 12 months d) Indefinitely Risk of VTE Recurrence After Cessation of VTE Risk factor 1st yr Next 5 yrs Distal DVT 3% (6%) <10% Majortransient 3% 10% Minortransient 5-6% 15% Unprovoked At least 10% 30% Recurrent > 10% > 30% Kearon, Blood 2005 21

Guidelines for Duration of Anticoagulation for VTE Indication 8th ACCP guidelines 2012 AHA 2010 British Hematology 2011 First episode of VTE secondary to a transient risk factor First episode of idiopathic (unprovoked) VTE 3 months (Grade 1B). At least 3 months, prefer long-term treatment if risk/benefit ratio ok (Grade 2B). 3 months (Class I Level A) 3 months At least 6 months, consider indefinite (Class I Level A) At least months;consider long term if risk benefit favors (2B) Recurrent VTE Long term (Grade 1B). Indefinite Class I Level A). Clinical presentation predicts likelihood and type of recurrence Distal (calf vein thrombosis) Low risk of recurrence/pe Proximal- nearly 5 fold increased recurrence risk over distal PE vs. DVT Patients presenting with PE are 3x more likely to suffer recurrent PE than those presenting with DVT Baglin T et al J Thromb Haemost. 2010 22

Individual Bleeding Risk on Anticoagulation Bleeding Risk Factors Age > 75 Previous GI bleed with no reversible cause Previous bleed on warfarin Renal/hepatic failure Antiplatelet therapy Cancer Case fatality rate VTE Case fatality rate of recurrent VTE highest in 1 st 3-6 months-11% Case fatality rate of recurrent VTE decreases after 3-6 months to 3.6% Carrier Ann Intern Med 2010 Case #5a/b:How long will you recommend these patients stay on anticoagulation? 55 yo man with unprovoked PE? a) 3 months b) 6 months c) 12 months d) Consider Indefinitely 68 yo woman with provoked PE? a) 3 months b) 6 months c) 12 months d) Indefinitely 23

Take Home Points When assessing for DVT use clinical probability and d-dimer (especially if not doing whole leg ultrasound) Order follow up ultrasound in appropriate high risk patients Consider age adjusted d-dimer in low/int probability PE patients over 50 Risk stratify all PE patients to determine disposition, triage and treatment Take Home Points Consider PESI48 to identify intermediate risk patients for abbreviated hospital stay In general, avoid expense of comprehensive testing for laboratory thrombophilia given limited role in determining duration of anticoagulation in VTE (except where it will impact recommendations/management) 24

Take Home Points Decision to use thrombolytics for submassive PE should be made on a case by case basis Duration of therapy for VTE event dictated by presence or absence of transient removable risk factor, individual bleeding risk and patient preference. Minimum effective duration for all scenarios is 3 months WORKSHOP Catheter related thrombosis Calf vein thrombosis Duration of anticoagulation for VTE Management of recurrent VTE Management of subsegmental PE When to restart anticoagulation after warfarin associated GI bleed IVC filters 25